对于HFrEF治疗的同步膜刺激-一篇评论
L R Goldberg1, M Mirro2, G Becker3
1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Lee.Goldberg@pennmedicine.upenn.edu.
Heart failure reviews
|May 28, 2025
概括
同步腹膜刺激为心力衰竭患者提供了新的希望. 这种微创治疗改善了运动耐受性,生活质量和心脏功能,目前正在接受FDA评估.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 再生医学是一种再生医学.
背景情况:
- 中度至重度心力衰竭患者往往缺乏有效的治疗选择,包括最大限度的医疗治疗和移植等先进的干预措施.
- 现有疗法可能无法完全解决这一群体的生活质量或疾病进展问题.
研究的目的:
- 审查同步腹膜刺激 (SDS) 治疗心力衰竭的新兴疗法.
- 突出SDS在改善患者结果和解决未满足的临床需求方面的潜力.
主要方法:
- 审查当前的临床结果和同步隔膜刺激的实施.
- 描述SDS交付的最小侵入性腹腔镜手术.
- 提到正在进行的美国FDA评估,包括计划进行双盲随机对照试验.
主要成果:
- 使用同步隔膜刺激的患者在6-12个月内表现出更好的运动耐受性.
- 观察到生活质量和血液动力学功能的显著改善.
- 该疗法是安全地通过一个微创性腹腔镜手术实施,通常在门诊基础上.
结论:
- 同步腹膜刺激是一种有前途的新疗法,用于中度至重度心力衰竭.
- 该程序是安全的,侵入性最小,并显示出改善患者血液动力学和生活质量的潜力.
- 突破性设备的指定和FDA评估的RCT表明显著的临床兴趣和广泛采用的潜力.
相关概念视频
Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41


